EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi

Lulu An, Gengpei Jia, Jingwen Tan, Lianjuan Yang, Yuemei Wang, Lei Li

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2023.1131416 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Lulu An und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Mycology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Antifungal Agents, Mycoses. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chromoblastomycosis (CBM) is a form of chronic mycosis that affects the skin and mucous membranes and is caused by species of dematiaceous fungi including Exophiala spp., Phialophora spp., and Fonsecaea spp. The persistence of this disease and limitations associated with single-drug treatment have complicated efforts to adequately manage this condition.

Methods

In this study, a microdilution assay was used to explore the synergistic antifungal activity of everolimus (EVL) in combination with itraconazole (ITC), voriconazole (VRC), posaconazole (POS), and amphotericin B (AMB) against a range of clinical dematiaceous fungal isolates.

Results

These analyses revealed that the EVL+POS and EVL+ITC exhibited superior in vitro synergistic efficacy, respectively inhibiting the growth of 64% (14/22) and 59% (13/22) of tested strains. In contrast, the growth of just 9% (2/22) of tested strains was inhibited by a combination of EVL+AMB, and no synergistic efficacy was observed for the combination of EVL+VRC.

Discussion

Overall, these findings indicate that EVL holds promise as a novel drug that can be synergistically combined with extant antifungal drugs to improve their efficacy, thereby aiding in the treatment of CBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsMycosesHumansEverolimusAmphotericin BVoriconazoleMicrobial Sensitivity TestsFungi

Stichwörter der Autor:innen

antifungalchromoblastomycosisdematiaceous fungieverolimussynergistic effect

Substanzen

Antifungal AgentsEverolimusAmphotericin BVoriconazole

Autor:innen und Institutionen

  • Department of Medical Mycology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
  • Department of General Medicine, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, China.
  • Department of Clinical Laboratory, Shibei Hospital, Shanghai, China.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

An, L., Jia, G., Tan, J., Yang, L., Wang, Y., & Li, L. (2023). Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1131416

Vancouver

An L, Jia G, Tan J, Yang L, Wang Y, Li L. Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1131416

BibTeX
@article{An2023,
  author = {An, Lulu and Jia, Gengpei and Tan, Jingwen and Yang, Lianjuan and Wang, Yuemei and Li, Lei},
  title = {Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1131416}
}
Kostenlos starten →